Latest news for Liechtensteinische (OTC:LLAZF) Stock

Liechtensteinische Landesbank AG is a universal banking and financial services group. The bank's business activities are divided into the following segments: Retail & Corporate Banking, and International Wealth Management. The company's product and services portfolio includes various financial services, such as payment processing, lending, mortgage, individual pension fund solutions, wealth planning, taxation, asset management, and investment advisory, among others. The company generates a majority of its revenue from the Retail & Corporate Banking segment, and more than half of its revenue is earned in Liechtenstein and the rest from Switzerland and Austria.

LIECHTENSTEINISCHE LANDBK by Liechtensteinische Landesbank Ag Vaduz

Liechtensteinische Landesbank AG

Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) shares are trading higher premarket on Friday after the company disclosed that its subsidiary, Beneficient Company Holdings, L.P., has completed a transaction where approximately $35 million of its preferred equity was redesignated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42133708/beneficient-consummates-transaction-to-increase-permanent-equity-by-35-million" rel="noreferrer noopener">as non-redeemable</a>.
This transaction resulted in the addition of approximately $35 million in permanent equity to the balance sheet.
Consequently, the company now believes it meets the Nasdaq Minimum Stockholders&#8217; Equity Requirement, with stockholders&#8217; equity of at least $2.5 million. However, Nasdaq&#8217;s final determination will confirm the company&#8217;s compliance.
Beneficient also announced the appointment of Karen J. Wendel as an independent member of its Board of <a target="_blank" href="https://www.benzinga.com//node/42133707" rel="noreferrer noopener">Directors as of November 21.</a>
Apart from this, Beneficient, through its subsidiary Beneficient Fiduciary Financial, L.L.C., provided an update to the State of Kansas Joint Committee on<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42126842/beneficient-reports-to-kansas-legislative-committee-on-its-positive-developments-and-the-digital-t" rel="noreferrer noopener"> Fiduciary Financial Institutions Oversight</a>.
The update highlighted the company&#8217;s business operations, digital innovations in the alternative asset industry, and its contributions to economic development in Kansas communities.
During its testimony, Beneficient executives reviewed the company&#8217;s fiscal second-quarter results for the period ending September 30, 2024, marking the second consecutive quarter of positive diluted earnings per share for its common shareholders.
The company highlighted advancements in its financial industry-focused business, including new technology innovations, an authorization from its board to complete up to $5 billion in fiduciary financings, and a transaction that reclassified certain preferred equity, increasing Beneficient&#8217;s permanent equity by $126 million.
The testimony also emphasized progress on key projects funded primarily by proceeds generated under the Kansas Technology-Enabled Fiduciary Financial Institutions (TEFFI) Act.
Price Action: BENF shares are up 18.2% at $1.04 premarket at the last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42134782" target="_blank" rel="noreferrer noopener">After Plunging 16%, MicroStrategy Makes Modest Recovery In Friday Pre-Market: Is There Still Hope For A $100K BTC Effect?</a></li>
</ul>

Equities

Large Cap

News

Legal

Movers

BENF

Beneficient Adds $35 Million In Permanent Equity, Aiming For Nasdaq Compliance

WIIM

BTAI

BioXcel Therapeutics shares are trading lower after the company announced a public offering valued at $7 million consisting of shares and warrants.

Offerings

INDP

Indaptus Therapeutics Announces $2.135M Registered Direct Offering And Private Placement, Issuing Shares And Warrants At $1.175 Per Unit, With Closing Expected November 25, 2024

Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment

Biotech

General

APVO

Aptevo Provided Details About Portfolio On Cancer Immunotherapy

HALO

Halozyme Therapeutics shares are trading higher after the company announced it withdrew plans to acquire Evotec.

Halozyme Withdraws €2B Proposal To Acquire Evotec After Evotec Declines Engagement, Citing Commitment To Independence; Halozyme Reaffirms 2024 Guidance And Strategic Growth Targets

Raymond James analyst Andrew Marok reiterates Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Strong Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

RBLX

Raymond James Reiterates Strong Buy on Roblox, Maintains $60 Price Target

Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) just disclosed its Q3 earnings on Friday, November 22, 2024 at 08:30 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Dynagas LNG Partners beat estimated earnings by 7.000000000000001%, reporting an EPS of $0.3 versus an estimate of $0.28.
Revenue was up $2.06 million from the same period last year.
<h3>Earnings History Overview</h3>
In the previous quarter, the company missed on EPS by $0.03, resulting in a 2.0% drop change in the share price the following day.
Here's a look at Dynagas LNG Partners's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.28</td>
<td>0.30</td>
<td>0.3</td>
<td>0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.25</td>
<td>0.25</td>
<td>0.2</td>
<td>0.01</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>37.91M</td>
<td>37.91M</td>
<td>38.21M</td>
<td>31.31M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>37.62M</td>
<td>38.05M</td>
<td>36.95M</td>
<td>37.01M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Dynagas LNG Partners <a href="https://www.benzinga.com/quote/DLNG/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

DLNG

Earnings Summary: Dynagas LNG Partners Q3

Raymond James analyst John Ransom downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Strong Buy to Outperform and maintains the price target from $195 to $195.

Downgrades

Raymond James Downgrades Tenet Healthcare to Outperform, Maintains Price Target to $195

SPPL

SIMPPLE Deploys 89 Autonomous Cleaning Robots Across Three Major MRT Lines In Singapore With SMRT Trains, Marking Largest Robotic Fleet In The Land Transport Sector

Contracts

ONDS

Ondas Receives Purchase Order For The Iron Drone Raider Counter-Drone System From An Israeli Defense Company

AESI

Atlas Energy Solutions shares are trading higher after the company announced it will join the S&P small-cap 600 and replace Mueller Industries.

Raymond James analyst John Ransom downgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Market Perform.

Raymond James Downgrades HCA Healthcare to Market Perform

JTAI

Jet.AI Announces Fleet Purchase Agreement With Textron Aviation  For The Purchase Of Three Cessna Citation CJ4 Gen2 Aircraft

Abacus Life shares are trading lower after the company announced a $100 public offering of 12.5 million shares.

VRPX

Virpax Reports Results For Swine Model Dose Range Finding Study For Probudur

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continues to defy expectations, not just as a trailblazer in the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle (EV) market</a> but also as a juggernaut in the stock market. 
With its stock up 45.02% over the past year, 36.72% year-to-date, and 55.82% in just the last month, TSLA stock has firmly established itself in bullish territory.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22065459/Screenshot-2024-11-22-at-5.24.46-PM.png" alt="" class="wp-image-660725" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22065459/Screenshot-2024-11-22-at-5.24.46-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22065459/Screenshot-2024-11-22-at-5.24.46-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The technical signals back this sentiment. Tesla&#8217;s stock price of $339.64 sits comfortably above its eight, 20 and 50-day simple moving averages, signaling a strong upward trend. The Moving Average Convergence/Divergence (MACD) indicator, at 25.85, underscores the stock's upward momentum, further supporting a bullish outlook.
Meanwhile, the Relative Strength Index (RSI) of 66.95 suggests TSLA is approaching overbought levels, reflecting a mix of optimism and caution among traders. However, the stock still appears to have room for upward movement in the near term.
Read Also: <a href="https://www.benzinga.com/24/11/42132485/hyundais-incoming-ceo-is-steadfast-on-evs-says-tesla-ceo-elon-musks-proximity-to-trump-will-be-good-for-industry">Tesla CEO Elon Musk&#8217;s Proximity To Trump Will Benefit EV Industry, Says Incoming Hyundai CEO As He Shrugs Off Potential Tariff Threats</a>
<h2 class="wp-block-heading">The Role Of China In Tesla's Stock Story</h2>
China, the largest EV market in the world, remains pivotal to Tesla's growth strategy. The Shanghai Gigafactory is not just a cornerstone of Tesla's global production but also a key revenue driver, contributing nearly a quarter of the company's total income.
While this reliance has helped Tesla dominate in China, it also makes the company vulnerable to U.S.-China trade tensions. If tariffs on key EV components like lithium-ion batteries escalate, it could squeeze Tesla's margins or limit its ability to pass on costs to consumers. 
However, Tesla's efforts to strengthen relationships with policymakers, both in the U.S. and abroad, may provide a safety net.
Investors have taken these geopolitical risks in stride, and TSLA stock has shown resilience even as broader market uncertainty persists.
<h2 class="wp-block-heading">Investor Outlook: TSLA In The Driver's Seat</h2>
For TSLA stock investors, the outlook remains compelling. The combination of strong technical momentum and Tesla's strategic position in the EV market suggests further room for growth. However, rising trade tensions and the stock nearing overbought territory suggest cautious optimism.
As Tesla balances its global ambitions with domestic trade policies, the company's ability to navigate these challenges will likely shape its stock's trajectory. 
For now, the technicals remain firmly bullish, and TSLA investors are keeping their eyes on the road ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Technicals

Markets

Tech

Trading Ideas

TSLA

Tesla Gains 55% In A Month With Strong China Role, Bullish Signals

Raymond James analyst John Ransom downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Strong Buy to Outperform and announces $195 price target.

Raymond James Downgrades Tenet Healthcare to Outperform, Announces $195 Price Target

Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.28 by 7.14 percent. The company reported quarterly sales of $39.069 million which beat the analyst consensus estimate of $38.335 million by 1.91 percent. This is a 5.56 percent increase over sales of $37.012 million the same period last year.

Earnings Beats

Dynagas LNG Partners Q3 2024 Adj. EPS $0.30 Beats $0.28 Estimate, Sales $39.069M Beat $38.335M Estimate

SOAR

Volato's Vaunt Platform Achieves 50% ARR Growth, Expands Inventory With flyExclusive's Excel/XLS Aircraft, Adding Up To 58 Jets To Enhance Luxury Private Travel And Drive Further Growth

Liechtensteinische

Comments

Liechtensteinische

News

Latest news for Liechtensteinische (OTC:LLAZF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga